Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2833234 | Molecular Immunology | 2006 | 4 Pages |
Abstract
Atypical haemolytic uraemic syndrome (aHUS) is a disorder of complement dysregulation. Because complement factor B (fB) carries the catalytic site of the alternative pathway convertase we examined it as both a potential candidate gene and modifier in the pathogenesis of aHUS. No factor B gene (BF) mutations were found in 20 patients with aHUS. There was no statistical difference between controls and aHUS patients in either BF allele or haplotype frequency. In conclusion, in this small series of aHUS patients we found no evidence that fB has a major role in the pathogenesis of aHUS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Biology
Authors
David Kavanagh, Elizabeth J. Kemp, Anna Richards, Rachel M. Burgess, Elizabeth Mayland, Judith A. Goodship, Timothy H.J. Goodship,